echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xianju Pharmaceutical's Flumazenil Injection Passed the Consistency Evaluation of Generic Drugs

    Xianju Pharmaceutical's Flumazenil Injection Passed the Consistency Evaluation of Generic Drugs

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 11, Xianju Pharmaceutical announced that it had recently received the "Approval Notice for Supplementary Drug Application" for Flumazenil Injection approved and issued by the State Food and Drug Administration.


    Flumazenil is a selective gamma-aminobutyric acid type A receptor (GABAA) antagonist, which recognizes BDZ receptor drugs by competitively inhibiting the gamma-aminobutyric acid-benzodiazepine complex (GABA-BDZ), and then It reduces the release of γ-aminobutyric acid (GABA) and reverses the central inhibitory effect of GABA release.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.